ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
November 21, 2019 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 21, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of...
ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
September 09, 2019 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of...
First Clinical Program Initiated Using Nanoparticles to Treat Retinitis Pigmentosa
April 23, 2019 11:00 ET
|
2Ctech, Inc.
IRVINE, Calif., April 23, 2019 (GLOBE NEWSWIRE) -- 2Ctech, Inc., a privately-held development stage company focused on the application of nanoparticle technologies for the treatment of retinal...
ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2
March 11, 2019 08:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticals
October 29, 2018 07:33 ET
|
ProQR Therapeutics N.V.
ProQR receives exclusive worldwide license for IONIS-RHO-2.5Rx, now QR-1123, for autosomal dominant retinitis pigmentosa (adRP), a rare inherited form of blindness with no approved therapy A first in...
Drug Candidates in Retinitis Pigmentosa Therapeutics Pipeline to Develop More as Gene Therapy: P&S Market Research
March 27, 2018 05:39 ET
|
P&S Market Research
NEW YORK, March 27, 2018 (GLOBE NEWSWIRE) -- According to a new research report titled “Retinitis Pigmentosa Therapeutics Pipeline Analysis, 2017” published by P&S Market Research, Retinitis...
GenSight Biologics Enrolls First Patient in Pivotal Phase III Program of GS010 in Leber’s Hereditary Optic Neuropathy
February 29, 2016 07:00 ET
|
GenSight Biologics
PARIS, Feb. 29, 2016 (GLOBE NEWSWIRE) -- GenSight Biologics S.A. (GenSight), a clinical-stage biotechnology company discovering and developing novel gene therapies for neurodegenerative retinal...
UCHealth Eye Center Restores Limited Sight to Blind Patient with Region's First Bionic Eye Surgery
December 10, 2015 09:10 ET
|
UCHealth
AURORA, Colo., Dec. 10, 2015 (GLOBE NEWSWIRE) -- The UCHealth Eye Center at University of Colorado Hospital has performed the first "bionic eye" procedure in the Rocky Mountain region, restoring...
Sucampo Announces Completion of Patient Enrollment in a Phase 3 Clinical Study of Unoprostone Isopropyl for Retinitis Pigmentosa
October 21, 2013 20:00 ET
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Oct. 21, 2013 (GLOBE NEWSWIRE) -- Sucampo AG, a subsidiary of Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo"), today announced that its development partner, R-Tech Ueno, Ltd....
Second Sight Reaches Middle East: Another Major Milestone for Blind People With Retinitis Pigmentosa
March 06, 2013 03:00 ET
|
Second Sight Medical Products Inc.
LAUSANNE, Switzerland, and RIYADH, Saudi Arabia, March 6, 2013 (GLOBE NEWSWIRE) --
Dr. Fernando Arevalo, Adjunct Professor of Ophthalmology at Wilmer Eye Institute (Retina Division) at Johns...